Clinical trial NCT02464163: Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older
Official title: Phase 1/2 Adaptive Design Trial to Evaluate the Immunogenicity and Safety of Panblok (H7 rHA) at Three Dose Levels Adjuvanted With a Stable Oil-in-Water Emulsion Compared With Unadjuvanted H7 rHA in Healthy Adults Aged 18 and Older
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Influenza
Keywords: Influenza
Lead sponsor: Protein Sciences Corporation
Sponsor class: INDUSTRY
First posted: 2015-06-08
Enrollment: 407
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to investigate the safety and immunogenicity of a recombinant hemagglutinin (rHA) influenza vaccine derived from A/Anhui/1/2013 (H7N9) administered at 3 dose levels in adjuvanted (SE) rHA formulations and 1 dose levels in an unadjuvanted rHA formulation.

Detailed description: All currently licensed influenza vaccines in the United States are produced in embryonated hen's eggs. There are several well-recognized disadvantages to the use of eggs as the substrate for influenza vaccine. Eggs require specialized manufacturing facilities and could be difficult to scale up rapidly in response to an emerging need such as a pandemic. It is usually necessary to adapt candidate vaccine viruses for high-yield growth in eggs, a process that can be time consuming, is not always successful, and can select receptor variants that may have suboptimal immunogenicity. In addition, agricultural diseases that affect chicken flocks, and that might be an important issue in a pandemic due to an avian influenza virus strain, could easily disrupt the supply of eggs for vaccine manufacturing. Therefore, development of alternative substrates for influenza vaccine production has been identified as a high-priority objective.

One potential alternative method for production of influenza vaccine is expression of the influenza virus hemagglutinin (HA) using recombinant DNA techniques. This alternative avoids dependence on eggs and is very efficient because of the high levels of protein expression under the control of the baculovirus polyhedrin promoter.

Eligibility criteria: Inclusion Criteria:

1. Adults, regardless of gender, aged 18 years and above
2. Able to give written informed consent to participate.
3. Body temperature \<100.0ºF.
4. The subject must be in reasonably good health as determined by targeted physical examination, when necessary, based on medical history.
5. Women of child-bearing potential (WOCBP) must have a negative urine pregnancy test within 24 hours preceding receipt of first and second vaccine doses.
6. Women are considered not of child-bearing potential if they are:

   * Surgically sterile
   * Menopausal, defined as no natural menses for ≥12 months
7. Comprehension of the study requirements, expressed availability for the required study period, and ability to attend scheduled visits and remote contacts.

Exclusion Criteria:

1. Persons who previously received an H5N1 or H7N9 influenza vaccine or who plan to receive an H5N1or H7N9 influenza vaccine while participating in the study.
2. Persons who plan to receive a seasonal influenza vaccine earlier than Day 42 of participation in this study, i.e. before the post-vaccination serology sample is obtained.
3. Persons with an acute or chronic medical condition that, in the opinion of the investigator, would render vaccination unsafe or would interfere with the evaluation of immune responses.
4. Persons taking medications or treatments that may adversely affect the immune system, e.g. cytotoxic agents, immunosuppressive doses of corticosteroids, anti-TNFα agents.
5. Persons with an active neoplastic disease (excluding non-melanoma skin cancer that was successfully treated) or a history of any hematological malignancy. For this criterion, "active" is defined as having received treatment within the past 5 years.
6. Persons with a history of documented autoimmune disease.
7. Women currently pregnant, nursing mothers or women planning a pregnancy between enrollment and 42 days after randomization.
8. Persons who have had a prior serious reaction to any influenza vaccine.
9. Persons with a known history of Guillain-Barré Syndrome (GBS).
10. Persons with a history of anaphylactic-type reaction to injected vaccines.
11. Persons with a history of illicit drug use or alcohol abuse that may compromise the subject's ability to comply with the protocol.
12. Persons who received a seasonal influenza vaccine \< 6 months prior to enrollment (may delay enrollment).
13. Persons who received any licensed inactivated or recombinant (non-live) vaccine within 2 weeks prior to enrollment or any licensed live vaccine within 1 month prior to enrollment (may delay enrollment) (See separate exclusion criteria #1 and #12 for seasonal and H5N1 influenza vaccines.)
14. Persons who have had an acute illness or fever (\>38º C or \>100º F) within three days prior to study enrollment (enrollment may be delayed for full recovery, if acceptable to investigator).
15. Persons currently participating or planning to participate in a study that involves an experimental agent (vaccine, drug, biologic, device, or medication) or have received an experimental agent within 1 month prior to enrollment in this study, or who expect to receive another experimental agent during participation, or intend to donate blood during the 42-day primary study period.
16. Persons who received immunoglobulin or another blood product within the 3 months prior to enrollment in this study. Persons who expect to receive immunoglobulin or another blood product during the 42-day primary period of this study.

Primary outcomes:
measure: Demonstrate That the Immunogenicity of Adjuvanted Panblok H7 rHA is Sufficient to Support Emergency Use Authorization in the Event of a Declared Pandemic.
timeFrame: 42 Days
Secondary outcomes:
measure: Reactogenicity Immediately After Each Injection, Extending to Day 7
timeFrame: 7 Days
measure: Long-term Safety Assessed by Incidence of SAEs, NOCIs. AESs Over 12 Months Following Vaccination
timeFrame: 13 months
measure: Unsolicited Adverse Events (UAEs) During Days 0-42 Following the First Administration of Study Vaccine
timeFrame: 42 Days
Other outcomes:
Locations:
city: Mobile
country: United States
facility: Coastal Clinical Research
state: Alabama
city: DeLand
country: United States
facility: Avail Clinical Research
state: Florida
city: Savannah
country: United States
facility: Meridian Clinical Research
state: Georgia
city: Omaha
country: United States
facility: Meridian Clinical Research
state: Nebraska
city: Endwell
country: United States
facility: Regional Clinical Research, Inc.
state: New York
city: Cleveland
country: United States
facility: Rapid Medical Research, Inc.
state: Ohio
city: Austin
country: United States
facility: Benchmark Reseach
state: Texas
city: Fort Worth
country: United States
facility: Benchmark Research - Fort Worth
state: Texas
city: Salt Lake City
country: United States
facility: Jean Brown Research
state: Utah
Study officials:
affiliation: University of Rochester Center for Vaccine Studies
name: John J Treanor, MD
role: PRINCIPAL_INVESTIGATOR
References: